Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-40-560810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$403.62 million
Profitability
Miscellaneous
Employees2,617
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Evotec (ETR:EVT) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the ETR under the ticker symbol "EVT."
When is Evotec's next earnings date?
What price target have analysts set for EVT?
3 brokers have issued 1-year price objectives for Evotec's stock. Their predictions range from €25.00 to €28.00. On average, they anticipate Evotec's stock price to reach €26.33 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View Analyst Price Targets for Evotec.
What is the consensus analysts' recommendation for Evotec?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
Headlines about EVT stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evotec earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Evotec.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include Bausch Health Companies (BHC), Canopy Growth (WEED), Aurora Cannabis (ACB), Hikma Pharmaceuticals (HIK), Aphria (APHA), Hexo (HEXO), Knight Therapeutics (GUD), Ecofibre (EOF), OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), HLS Therapeutics (HLS), Supreme Cannabis (FIRE), Green Organic Dutchman (TGOD) and Benchmark (BMK).
What other stocks do shareholders of Evotec own?
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
- Dr. Craig Johnstone, COO & Member of Management Board
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
What is Evotec's stock price today?
One share of EVT stock can currently be purchased for approximately €19.92.
How big of a company is Evotec?
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.
MarketBeat Community Rating for Evotec (ETR EVT)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
